Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer

JHOP - February 2023 Vol 13, No 1 - FDA Oncology Update

On January 26, 2023, the FDA approved pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non–small-cell lung cancer (NSCLC), after resection and platinum-based chemotherapy.

Pembrolizumab monotherapy was previously approved for first-line treatment in patients with NSCLC and PD-L1 expression but without ALK or EGFR mutations, and for patients with metastatic NSCLC and PD-L1 expression, after platinum-based chemotherapy.

The FDA approval of pembrolizumab monotherapy for adjuvant therapy in patients with NSCLC was based on the results of the multicenter, randomized, triple-blind, placebo-controlled KEYNOTE-091 clinical trial of patients who had not received neoadjuvant radiotherapy or chemotherapy. The patients were randomized (1:1) to adjuvant treatment with pembrolizumab 200 mg or to placebo intravenously every 3 weeks for up to 1 year. Of the 1177 patients in the study, 1010 (86%) patients received adjuvant platinum-based chemotherapy after complete resection.

The main end point was disease-free survival (DFS). The results showed a significant improvement in DFS with pembrolizumab versus placebo in the overall population. Among patients who received adjuvant chemotherapy, the median DFS was 58.7 months in the pembrolizumab arm (95% confidence interval [CI], 39.2-not reached) versus 34.9 months in the placebo arm (95% CI, 28.6-not reached; hazard ratio [HR], 0.73; 95% CI, 0.60-0.89). In a subgroup analysis of 167 patients who did not receive adjuvant chemotherapy, the HR for DFS was 1.25 (95% CI, 0.76-2.05).

The adverse events in KEYNOTE-091 were similar to those seen with pembrolizumab monotherapy in patients with NSCLC, with the exception of hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%). In addition, myocarditis led to 2 deaths.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: